234 related articles for article (PubMed ID: 27018341)
61. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
62. Target of rapamycin signaling in leukemia and lymphoma.
Vu C; Fruman DA
Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
[TBL] [Abstract][Full Text] [Related]
63. Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model.
Hasan MN; Queudeville M; Trentin L; Eckhoff SM; Bronzini I; Palmi C; Barth T; Cazzaniga G; te Kronnie G; Debatin KM; Meyer LH
Oncotarget; 2015 Jan; 6(3):1382-95. PubMed ID: 25682198
[TBL] [Abstract][Full Text] [Related]
64. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
65. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
66. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.
Reikvam H; Tamburini J; Skrede S; Holdhus R; Poulain L; Ersvaer E; Hatfield KJ; Bruserud Ø
Br J Haematol; 2014 Jan; 164(2):200-11. PubMed ID: 24383842
[TBL] [Abstract][Full Text] [Related]
67. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
Vakana E; Platanias LC
Oncotarget; 2011 Dec; 2(12):1322-8. PubMed ID: 22249159
[TBL] [Abstract][Full Text] [Related]
68. Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Ge Z; Song C; Ding Y; Tan BH; Desai D; Sharma A; Gowda R; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Iyer S; Dhanyamraju PK; Imamura Y; Bogush D; Bamme Y; Yang Y; Soliman M; Kane S; Dovat E; Schramm J; Hu T; McGrath M; Chroneos ZC; Payne KJ; Gowda C; Dovat S
Leukemia; 2021 May; 35(5):1267-1278. PubMed ID: 33531656
[TBL] [Abstract][Full Text] [Related]
69. Targeting mTOR in Acute Lymphoblastic Leukemia.
Simioni C; Martelli AM; Zauli G; Melloni E; Neri LM
Cells; 2019 Feb; 8(2):. PubMed ID: 30795552
[TBL] [Abstract][Full Text] [Related]
70. [PI3K/AKT/mTOR Pathway and Pediatric T Acute Lymphoblastic Leukemia-Review].
Shi LX; Wang JH; Shi XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1269-74. PubMed ID: 27531814
[TBL] [Abstract][Full Text] [Related]
71. Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer.
Tufail M; Wan WD; Jiang C; Li N
Chem Biol Interact; 2024 Jun; 396():111055. PubMed ID: 38763348
[TBL] [Abstract][Full Text] [Related]
72. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses.
Bent EH; Gilbert LA; Hemann MT
Genes Dev; 2016 Aug; 30(16):1811-21. PubMed ID: 27566778
[TBL] [Abstract][Full Text] [Related]
73. Resistance of THP-1 Leukemia Cells Infected with Cytomegalovirus to Anti-tumor Antibiotic Doxorubicin and Restoration of the Sensitivity by Inhibitors of the PI3K/AKT/mTOR Molecular Pathway.
Chernoryzh YY; Fedorova NE; Yurlov KI; Simonov RA; Kornev AB; Karpov DS; Zakirova NF; Ivanov AV; Kushch AA; Gintsburg AL
Dokl Biochem Biophys; 2019 Nov; 489(1):388-391. PubMed ID: 32130607
[TBL] [Abstract][Full Text] [Related]
74. Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia.
Ricciardi MR; Mirabilii S; Licchetta R; Piedimonte M; Tafuri A
Adv Biol Regul; 2017 Aug; 65():36-58. PubMed ID: 28549531
[TBL] [Abstract][Full Text] [Related]
75. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
Carroll WL; Aifantis I; Raetz E
Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
[TBL] [Abstract][Full Text] [Related]
76. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
[TBL] [Abstract][Full Text] [Related]
77. Targeted delivery of AZD5363 to T-cell acute lymphocytic leukemia by mSiO
Yang A; Luo D; Jia Y; Liu Y; Zhang Z; Li S; Liu R; Zhou J; Wang J
Colloids Surf B Biointerfaces; 2023 Oct; 230():113505. PubMed ID: 37574619
[TBL] [Abstract][Full Text] [Related]
78. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
Shi X; Li S; Tang S; Lu Y
Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
[TBL] [Abstract][Full Text] [Related]
79. mTOR, a new therapeutic target in acute myeloid leukemia.
Récher C; Dos Santos C; Demur C; Payrastre B
Cell Cycle; 2005 Nov; 4(11):1540-9. PubMed ID: 16205124
[TBL] [Abstract][Full Text] [Related]
80. Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Ridges S; Heaton WL; Joshi D; Choi H; Eiring A; Batchelor L; Choudhry P; Manos EJ; Sofla H; Sanati A; Welborn S; Agarwal A; Spangrude GJ; Miles RR; Cox JE; Frazer JK; Deininger M; Balan K; Sigman M; Müschen M; Perova T; Johnson R; Montpellier B; Guidos CJ; Jones DA; Trede NS
Blood; 2012 Jun; 119(24):5621-31. PubMed ID: 22490804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
